Comprehensive analysis of RET and ROS1 rearrangement in lung ...
We performed simultaneous screening of ALK, ROS1, and RET fusions in 295 lung adenocarcinoma specimens by direct, digital transcript profiling using the NanoString's nCounter technology, as described in a previous study.16 In addition, we collected 500 ...
Nature.com - Fri, 19 Sep 2014 04:36

Surveillance of Barrett's Esophagus and Mortality From Esophageal ...
Objectives: Barrett's esophagus (BE) is associated with an increased risk of developing esophageal adenocarcinoma (EAC). Patients with a known diagnosis of BE are usually advised to participate in an endoscopic surveillance program, but its clinical ...
Medscape - Mon, 01 Sep 2014 21:07



Understanding Bladder Cancer -Adenocarcinoma
Adenocarcinoma, this is a cancer that begins in glandular (secretory) cells that may form in the bladder after long-term irritation and inflammation. This type of bladder cancer is rare in the United States. There are other types of bladder cancer ...
Cancer - Sun, 14 Sep 2014 22:03

New oesophageal adenocarcinoma guidelines
Cancer Council Australia has published new clinical guidelines aimed at providing consistency in the management of Barrett's oesophagus and oesophageal adenocarcinoma (OAC). The guidelines, which the council says are the first of their kind in ...
Gastroenterology Update - Mon, 15 Sep 2014 18:30

Lung Adenocarcinoma-Pipeline Insights, 2014
A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Lung Adenocarcinoma. This report provides information on the therapeutic development based on the Lung Adenocarcinoma dealing with all the ...
PR Newswire (press release) - Wed, 03 Sep 2014 12:07

Erlotinib feasible in KRAS wild-type lung adenocarcinoma
Erlotinib is a valid treatment option for patients with KRAS wild-type lung adenocarcinoma refractory to chemotherapy, study data show. To determine the clinical significance of KRAS mutational status in response to erlotinib, Balazs Dome (Medical ...
News-Medical.net - Thu, 21 Aug 2014 14:11

Hotspot activating PRKD1 somatic mutations in polymorphous low-grade ...
Polymorphous low-grade adenocarcinoma (PLGA) is the second most frequent type of malignant tumor of the minor salivary glands. We identified PRKD1 hotspot mutations encoding p.Glu710Asp in 72.9% of PLGAs but not in other salivary gland tumors.
Nature.com - Sun, 21 Sep 2014 14:43

Immunohistochemical analysis of cancer stem cell markers in pancreatic ...
Cancer stem cells (CSCs) have been reported to play an important role in chemoradiation resistance. Although the association of CSC markers with clinicopathological outcomes after neoadjuvant chemoradiotherapy (NACRT) has been reported in various ...
7thSpace Interactive (press release) - Sat, 20 Sep 2014 18:18


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014